Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (41-50 of 174) with videos related to

Pageof 18
Sort By:
Gynecologic Oncology|December 30, 2014
The role of systemic chemotherapy in the management of granulosa cell tumorsJane L Meisel, David M Hyman, Anjali Jotwani, et al.
British Journal of Cancer|November 15, 2018
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumoursAlison M Schram, Leena Gandhi, Monica M Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Oncotarget|February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated ToxicitiesAnne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
JCO Precision Oncology|September 11, 2020
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid TumorsEzra Y Rosen, Alison M Schram, Robert J Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid TumorsJessica J Tao, Nicholas A Cangemi, Vicky Makker, et al.
The American Journal of Surgical Pathology|July 19, 2017
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsJaclyn F Hechtman, Ryma Benayed, David M Hyman, et al.
JCO Precision Oncology|September 6, 2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal MetastasesRobin Guo, Mark Schreyer, Jason C Chang, et al.
Pageof 18

Showing results (41-50 of 174) with videos related to

Sort By:
Pageof 18
Gynecologic Oncology|December 30, 2014
The role of systemic chemotherapy in the management of granulosa cell tumorsJane L Meisel, David M Hyman, Anjali Jotwani, et al.
British Journal of Cancer|November 15, 2018
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumoursAlison M Schram, Leena Gandhi, Monica M Mita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Oncotarget|February 17, 2015
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trialsDavid M Hyman, Anne A Eaton, Mrinal M Gounder, et al.
Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated ToxicitiesAnne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
JCO Precision Oncology|September 11, 2020
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid TumorsEzra Y Rosen, Alison M Schram, Robert J Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid TumorsJessica J Tao, Nicholas A Cangemi, Vicky Makker, et al.
The American Journal of Surgical Pathology|July 19, 2017
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsJaclyn F Hechtman, Ryma Benayed, David M Hyman, et al.
JCO Precision Oncology|September 6, 2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal MetastasesRobin Guo, Mark Schreyer, Jason C Chang, et al.
Pageof 18